Sartorius超滤产品在生物医学纳米载体制备中的应用（二）
Sartorius超滤
设备
MWCO | 超滤目的 | 参考 文献 | |
Vivaspin® 20 | 100 kDa | 纯化和浓缩步骤 | 7 |
Vivaspin® 20 | 100 kDa | 清洗步骤 | 8 |
Vivaspin® 20 | 5 kDa | 纯化步骤 | 17 |
Vivaspin® 6 | 10 kDa | 分离纳米颗粒 | 染料和清洗 | 18 |
Vivaspin® | 10 kDa | 纯化步骤 | 19 |
Vivaspin® | 5 kDa、10 kDa | 纯化和浓缩 | 20, 21 |
Vivaspin® | 300 kDa和 50 kDa | (计数前) 从初始材料中分离出量子点-抗体偶联物 | 9 |
Vivaspin® | 30 kDa | 纯化和浓缩 | 22 |
Vivaspin® 20 | 3 kDa | 清洗 | 23 |
Vivaspin® | 10 kDa | 浓缩步骤 | 24 |
Vivaspin® 20 | 10 kDa | 浓缩步骤 | 3 |
Vivaspin® 20 | 100 kDa | 浓缩步骤 | 25 |
Vivaflow® 50 | 100 kDa | 纯化步骤 | 26 |
Vivaflow® 200 | 100 kDa | 缓冲液更换和浓缩步骤 | 27 |
Vivaspin® 20和500 | 100 kDa | 缓冲液更换和浓缩步骤 | 28 |
Vivaflow® 200 | 100 kDa | 缓冲液更换和浓缩步骤 | 29 |
Vivaspin® | 100 kDa | 缓冲液更换和浓缩步骤 | 30 |
Vivaspin® | 100 kDa | 外部缓冲液更换 | 2 |
Vivaflow® 50 | 100 kDa | 去除游离药物 | 31 |
Vivaspin® | 30 kDa | 分离游离物质和浓缩步骤 | 4 |
Vivaflow® | 去除表面活性剂 | 14 | |
Vivaspin® 500 | 3 kDa | 将游离药物与胶囊药物分离 (通过后续的紫外线-可见光分析进行药物结合定量) | 32 |
参考文献
1.Strebhardt, K & Ullrich,A:
Paul Ehrlich's magic bullet concept: 100 years of progress8, 473- 480 (2008).
2.Jakoby,J.. Beuschlein, F., Mentz, S. Hantel,C. & Süss, R:
Liposomal doxorubicin for active targeting: Surface modification of the nanocarrier evaluated in vitro and in vivochallenges and prospects Oncotarget 6, (2015).
3.Klermund, L, Poschenrieder,S &t Castiglione, K:
Simple surface functionalization of polymersomes usingnon-antibacterial peptide anchors. J. Nanobiotechnology14, 48 (2016).
4.Mulder, W.J. M. et al..
Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG-micelles.
Magn. Reson. Med. 58,11641170(2007).
5.Murthy.S. K:
Nanoparticles in modern medicine: state of the art and futurechallenges.
Int. J. Nanomedicine2, 129-41 (2007).
6.Voigt, R. & Fahr, A:
Pharmazeutische Technologie für Studium und Beruf. Deutscher Apotheker Verlag.10th Edition 2010).
7.Unterweger, H. etal:
Development and characterization of magnetic iron oxidenanoparticles with a cisplatin-bearing polymer coatingfor targeted drug delivery. IntJ Nanomedicine93659- 3676 (2014).
8.Park,W.etal:
Multi-modal transfection agent based on monodispersemagnetic nanoparticles for stem cell gene deliveryand tracking. Biomaterials 35, 72397247 (2014).
9.Chalmers, N.I. etal:
Use of quantum dot luminescent probes to achieve singlecellresolution of human oral bacteria in biofilms. Appl. Environ.Microbiol. 73, 630- 636 (2007).
10.Hoffman, L W... Andersson, G. G., Sharma, A., Clarke,S.R & Voelcker,N. H.:
New insights into the structure of PAMAM dendrimer/goldnanoparticle nanocomposites. Langmuir 27, 6759- 6767(2011).
11.Rademacher, T. & Williams, P.:Nanoparticle -peptide compositions. (2014).
12.Allard, E. & Larpent, C: 24Core shell type dually fluorescent polymer nanoparticles forratiometric pH-sensing. J. Polym. Sei. Part A Polym. Chem.46,62066213 (2008).
13.Prach, M.. Stone,V. & Proudfoot,L:Zinc oxide nanoparticles and monocytes: Impact of size,charge and solubility on activation status. Toxicol. ApplPharmacol. 266, 19 -26 (2013).
14 Zhang,Y. etal:Therapeutic surfactant- stripped frozen micelles. Nat Commun, 11649 (2016).
15.Klasson,A. et al:Positive MRI contrast enhancement inTHP-1 cells withGd2O3 nanoparticles. Contrast Media Mol. lmaging3.1061112008).
16.Simonoska Crcarevska, M. et al:Definition of formulation design space, in vitro bioactivityand in vivo biodistribution for hydrophilic drug loaded PLGA/PEOPPO-PEO nanoparticles using OFAT experiments.Eur.. J. Pharm. Sei. 49, 65- -80 (2013).
17.Boda,S.K etal.:Cytotoxicity of Ultrasmall Gold Nanoparticles on Planktonicand Biofilm Encapsulated GramPositive Staphylococci.Small 1, 31833193 (2015).
18. Schäffler, M.et al:Blood protein coating of gold nanoparticles as potential toolfor organ targeting. Biomaterials 35, 3455 3466 (2014).
19.Arosio,D. etal.:.Effective targeting of DC sign by a-fucosylamide functionalized gold nanoparticles. Bioconjug. Chem.25,2244-2251(2014)
20.Miladi,l etal.:Biodistribution of ultra small gadolinium-based nanoparticlesas theranostic agent: application to brain tumors. J. Biomater.Appl.28, 38594 (2013).
21.Faure,ACetal Control of the in vivo biodistribution of hybrid nanoparticleswith different poly(ethylene glycol) coatings. Small5,2565- 2575 (2009).
22.Benita, S., Debotton, N. & Goldstein, D.:
Nanoparticles for Targeted Delivery of Active Agent. (2008).
23.Tukulula, M. et al:
Curdlan-conjugated PLGA nanoparticles possess macrophagestimulant activity and drug delivery capabilities. Pharm. Res.32.27132726 (2015).
24.Ernsting. M. J., Tang, W. L, MacCallum,N W.&Li,S. D:
Preclinical pharmacokinetic, biodistribution and anticancerefficacy studies of a docetaxel-carboxymethycellunanoparticle in mouse mooels. Biomaterials 33,14451454 (2012).
25.Geelen,T., Paulis,L E., Coolen, B. F., Nicolay, K & Strijkers,G.J:
Passive targeting of lipid-based nanoparticles to mousecardiac ischemia-reperfusion injury. Contrast Media Mol.Imaging8, 117-126 (2013).
26.Neves,A. R., Queiroz,J.F. & Reis, S:
Brain-targeted delivery of resveratrol using solid lipidnanoparticles functionalized with apolipoproteinEJNanobiotechnology 14, 27 (2016).
27.BogomoIny.E. et al:
Analysis of bacteria derived outer membrane vesicles usingtunable resistive pulse sensing. Prog. Biomed. Opt. Imaging =Proc. SPIE 9338, 4-9 (2015)
28.Blenkiron,C. etal..Uropathogenic Escherichia coli releases extracellular vesiclesthat are associated with RNA. PLoS One 11, 116 (2016).
29.Twu,O.etal Trichomonas vaginalis Exosomes Deliver Cargo to Host Cellsand Mediate Host:Parasite Interactions. PLoS Pathog.9,2224 (2013).
30.Tong.T. T.. Mörgelin, M.. Forsgren, A. & Riesbeck, K.:
Haemophilus influenzae Survival during Complement-Mediated Attacks Is Promoted by Moraxeila catarrhalis OuterMembrane Vesicles. J. Infect. Dis. 195, 16611670 (2007).
31.Prado, J. M. D.. Antoranz,J.R. C. Barroeta, M.Á.E..Barroeta, B. E. & Diaz, M.C.:Liposomal formulations. (2009).
32.Achilli,E. etal..Preparation of protein nanoparticle by dynamic aggregation
and ionizing-induced crosslinking. Colloids SurfacesA
Physicochem. Eng. Asp. 486, 161171 (2015).
